This article is more than 5 years old. Information may no longer be current.

Study: Postop anti-inflammatory use did not affect PCO

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Use of topical steroidal and nonsteroidal anti-inflammatory drugs after phaco and IOL implantation did not affect the formation of posterior capsular opacification during 2 years of follow-up, a prospective study found.

Anna Zaczek, MD, PhD and colleagues at St. Erik’s Eye Hospital in Stockholm, Sweden, measured aqueous flare intensity preoperatively and out to 2 years postop among patients who were given diclofenac, dexamethasone or a placebo for up to 3 weeks following cataract surgery.

At 2 years follow-up, no significant differences between groups were seen in PCO formation. Median rates of PCO, as measured by the Evaluation of Posterior Capsular Opacification system, were 0.72 for dexamethasone-treated patients, 0.78 for diclofenac-treated patients and 0.7 for patients receiving placebo (P > .05).

The authors noted that there were also no significant differences between groups in rates of Nd:YAG capsulotomy.

The study is published in the Journal of Cataract and Refractive Surgery.